Blood cancers

Podcast: Does ‘fit and unfit’ still fit with novel therapies in first-line CLL?


The use of novel agents in first-line chronic lymphocytic leukaemia is changing the way we manage patients. In this podcast we continue the conversation with Professor Paolo Ghia, Associate Professor in Internal Medicine at the Università Vita-Salute San Raffaele and local haematologist, Professor Stephen Opat, a Member of the Monash Health Translation Precinct about the changes novel therapies are bringing in the screening, stratification and first-line treatment of CLL.

This podcast was sponsored by Janssen. The content is based on published studies and the opinions of independent experts. The views expressed are not necessarily those of Janssen. 

 

PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING (available from www.janssen.com.au/Imbruvica_PI).

Already a member?

Login to keep reading.

OR
Email me a login link
logo

© 2022 the limbic